-transparent.png){kind=logo}
Perhexiline maleate (Pexid) which has been in general use in France with good results for the treatment of angina pectoris since 1973, may be associated with severe side effects including peripheral neuropathy. The present study is a comparison of the pharmacokinetics of perhexiline maleate in anginal patients with and without signs of peripheral neuropathy. Compared to the latter, those with neuropathy had higher plasma levels of perhexiline, slower hepatic metabolism and a longer plasma half-life. Thus, peripheral neuropathy associated with perhexiline maleate treatment appears to be a direct toxic effect due to accumulation of the drug. The accumulation might result either from a decreased volume of distribution secondary to a loss of body weight, possibly drug-induced, or to slow hepatic metabolism of perhexiline of genetic origin or due to hepatic disease, possibly drug-induced. The neuropathy is rarely an isolated event, as it is often associated with one or more adverse effects of perhexiline.
E Singlas, and
M A Goujet, and
P Simon
May 1979,
Neurology,
E Singlas, and
M A Goujet, and
P Simon
August 1982,
Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,
E Singlas, and
M A Goujet, and
P Simon
September 1977,
British medical journal,
E Singlas, and
M A Goujet, and
P Simon
March 1974,
Current therapeutic research, clinical and experimental,
E Singlas, and
M A Goujet, and
P Simon
April 1973,
Postgraduate medical journal,
E Singlas, and
M A Goujet, and
P Simon
June 1981,
Journal of the American Geriatrics Society,
E Singlas, and
M A Goujet, and
P Simon
January 1977,
Annales de cardiologie et d'angeiologie,
E Singlas, and
M A Goujet, and
P Simon
November 1985,
Annals of clinical biochemistry,
E Singlas, and
M A Goujet, and
P Simon
October 1975,
La Nouvelle presse medicale,
E Singlas, and
M A Goujet, and
P Simon
June 1977,
Lancet (London, England),
